Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to -$395000.0.

  • Phathom Pharmaceuticals' Change in Inventory fell 19449.76% to -$395000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year increase of 9560.47%. This contributed to the annual value of $6.1 million for FY2024, which is 3495.02% down from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Change in Inventory is -$395000.0, which was down 19449.76% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Change in Inventory registered a high of $12.3 million during Q1 2025, and its lowest value of -$395000.0 during Q3 2025.
  • For the 3-year period, Phathom Pharmaceuticals' Change in Inventory averaged around $3.3 million, with its median value being $418000.0 (2024).
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Change in Inventory showed a top increase of 286346.15% in 2025 and a maximum decrease of 19449.76% in 2025.
  • Quarter analysis of 3 years shows Phathom Pharmaceuticals' Change in Inventory stood at $9.3 million in 2023, then plummeted by 40.24% to $5.6 million in 2024, then crashed by 107.08% to -$395000.0 in 2025.
  • Its Change in Inventory stands at -$395000.0 for Q3 2025, versus $1.8 million for Q2 2025 and $12.3 million for Q1 2025.